In July, the six viral marker assay conversion at CTS Dallas, Phoenix and Tampa laboratories was achieved with minimal disruption and substantial cost saving to our healthcare partners.
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...
CTS Research Consortium was established to further CTS’s leadership in infectious disease research....
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
As a component of the CTS Business Continuity Plan, today all 6 labs began using the same laboratory...